Top Buy Now Summary References
Home
>
Section
>
Chapter

A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19

Mashayekhi-Sardoo, H.; Hosseinjani, H.

Journal of Basic and Clinical Physiology and Pharmacology 33(1): 17-25

2021

ISSN/ISBN: 2191-0286
PMID: 34218545
DOI: 10.1515/jbcpp-2020-0495
Accession: 080358497

Full-Text Article emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Summary
Since December 2019, the COVID-19 emerging pandemic caused by SARS-CoV-2 has resulted in one of the most important global health threats. Concerning the absence of an approved effective vaccine or drug for the treatment and outcome improvement of COVID-19 patients, and the role of SARS-CoV-2 in activation of mammalian target of rapamycin (mTOR) pathway, we decided to review the previous data regarding the therapeutic effect of mTOR inhibitor drugs in COVID-19 patients. We searched the scientific databases such as Web of Science, Embase, Medline (PubMed), Scopus, and Google Scholar using appropriate keywords to find suitable studies or suggestions until October 2020. The findings of the current study confirmed that mTOR inhibitor drugs through suggested mechanisms such as T cell adjustment, induction of autophagy without apoptosis, reduction of viral replication, restoration of the T-cell function, decrease cytokine storm, and moderation of the mTOR-PI3K-AKT pathway activation bring about a therapeutic impact in COVID-19 patients. Taken together, it is necessary to find a suitable therapy for the COVID-19 pandemic emerging. In this regard, we clarify that it is valuable to consider the therapeutic effect of mTOR inhibitor drugs and metformin by its mTOR inhibition property in the treatment of COVID-19 patients.

References

Dechtman, I.-D.; Ankory, R.; Sokolinsky, K.; Krasner, E.; Weiss, L.; Gal, Y. 2023: Clinically Evaluated COVID-19 Drugs with Therapeutic Potential for Biological Warfare Agents Microorganisms 11(6)
López-Arencibia, A.; Bethencourt-Estrella, C.J.; San Nicolás-Hernández, D.ée.; Lorenzo-Morales, J.; Piñero, J.é E. 2024: Anti-COVID Drugs (MMV COVID Box) as Leishmanicidal Agents: Unveiling new Therapeutic Horizons Pharmaceuticals 17(3)
Sankhala, K.; Giles, F.J. 2009: Potential of mTOR inhibitors as therapeutic agents in hematological malignancies Expert Review of Hematology 2(4): 399-414
Sun, S.-Y. 2013: MTOR kinase inhibitors as potential cancer therapeutic drugs Cancer Letters 340(1): 1-8
Kuo, C.-J.; Huang, C.-C.; Chou, S.-Y.; Lo, Y.-C.; Kao, T.-J.; Huang, N.-K.; Lin, C.; Lin, H.-C.; Lin, H.-C.; Lee, Y.-C. 2019: Potential therapeutic effect of curcumin, a natural mTOR inhibitor, in tuberous sclerosis complex Phytomedicine: International Journal of PhytoTherapy and Phytopharmacology 54: 132-139
Kim, T.-H.; Choi, S.J.; Lee, Y.H.; Song, G.G.; Ji, J.D. 2012: Combined therapeutic application of mTOR inhibitor and vitamin D(3) for inflammatory bone destruction of rheumatoid arthritis Medical Hypotheses 79(6): 757-760
Simioni, C.; Cani, A.; Martelli, A.M.; Zauli, G.; Tabellini, G.; McCubrey, J.; Capitani, S.; Neri, L.M. 2014: Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation Oncotarget 5(20): 10034-10047
Raychaudhuri, S.K.; Raychaudhuri, S.P. 2014: MTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target Indian Journal of Dermatology 59(1): 67-70
Iida, S.; Miki, Y.; Ono, K.; Akahira, J.-i.; Nakamura, Y.; Suzuki, T.; Sasano, H. 2012: Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor Molecular and Cellular Endocrinology 350(1): 99-106
Lu, C.-C.; Chen, M.-Y.; Lee, W.-S.; Chang, Y.-L. 2020: Potential therapeutic agents against COVID-19: what we know so far Journal of the Chinese Medical Association: Jcma 83(6): 534-536
Malin, J.J.; Bunse, T.; Spinner, C.D.; Protzer, U. 2022: Antiviral drugs : Potent agents, promising therapies for COVID‑19 and therapeutic limitations Der Internist 63(1): 118-128
Zaa, C.és.A.; Espitia, C.; Reyes-Barrera, K.L.; An, Z.; Velasco-Velázquez, M.A. 2023: Neuroprotective Agents with Therapeutic Potential for COVID-19 Biomolecules 13(11)
Ali, F.; Hussain, S.; Zhu, Y.Z. 2022: A Therapeutic Journey of Potential Drugs Against COVID-19 Mini Reviews in Medicinal Chemistry 22(14): 1876-1894
Kang, Y.; Wang, Q. 2022: Potential therapeutic value of necroptosis inhibitor for the treatment of COVID-19 European Journal of Medical Research 27(1): 283
Cao, J.; Liu, Y.; Zhou, M.; Dong, S.; Hou, Y.; Jia, X.; Lan, X.; Zhang, Y.; Guo, J.; Xiao, G.; Wang, W. 2022: Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19 Viruses 14(2)
Wu, Y.; Li, Z.; Zhao, Y.-S.; Huang, Y.-Y.; Jiang, M.-Y.; Luo, H.-B. 2021: Therapeutic targets and potential agents for the treatment of COVID-19 Medicinal Research Reviews 41(3): 1775-1797
Dong, X.; Tian, Z.; Shen, C.; Zhao, C. 2020: An overview of potential therapeutic agents to treat COVID-19 Bioscience Trends 14(5): 318-327
Turbanti, L.; Subissi, A.; Bramanti, G. 1982: Antimuscarinic drugs: traditional and potential new therapeutic agents Pharmacological Research Communications 14(10): 923-940
Patocka, J.; Fusek, J. 1992: Present trends in the development of drugs within the cholinesterase inhibitor group as therapeutic agents for Alzheimer's disease Ceskoslovenska Psychiatrie 88(5): 258-269
Yarbrough, G.G.; Taylor, D.P. 1991: Cell receptors as drugs. Ligand binding domains of receptors as drugs: a potential new class of therapeutic agents Journal of the Royal College of Physicians of London 25(4): 309-311